FR2907011B1 - USE OF CITRULLINE FOR THE TREATMENT OF DENUTRITION CONDITIONS - Google Patents

USE OF CITRULLINE FOR THE TREATMENT OF DENUTRITION CONDITIONS

Info

Publication number
FR2907011B1
FR2907011B1 FR0609077A FR0609077A FR2907011B1 FR 2907011 B1 FR2907011 B1 FR 2907011B1 FR 0609077 A FR0609077 A FR 0609077A FR 0609077 A FR0609077 A FR 0609077A FR 2907011 B1 FR2907011 B1 FR 2907011B1
Authority
FR
France
Prior art keywords
denutrition
citrulline
treatment
conditions
denutrition conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0609077A
Other languages
French (fr)
Other versions
FR2907011A1 (en
Inventor
Christophe Moinard
Marion Jourdan
Stephane Walrand
Luc Cynober
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de Recherche pour lAgriculture lAlimentation et lEnvironnement
Universite Paris Cite
Biocodex SAS
Original Assignee
Universite Paris 5 Rene Descartes
Biocodex SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0609077A priority Critical patent/FR2907011B1/en
Application filed by Universite Paris 5 Rene Descartes, Biocodex SAS filed Critical Universite Paris 5 Rene Descartes
Priority to US12/445,820 priority patent/US20100298437A1/en
Priority to PCT/FR2007/001407 priority patent/WO2008049984A2/en
Priority to CA002666538A priority patent/CA2666538A1/en
Priority to CNA2007800424825A priority patent/CN101605538A/en
Priority to JP2009532837A priority patent/JP2010506887A/en
Priority to EP07823453.1A priority patent/EP2081564B1/en
Publication of FR2907011A1 publication Critical patent/FR2907011A1/en
Priority to IL198182A priority patent/IL198182A0/en
Application granted granted Critical
Publication of FR2907011B1 publication Critical patent/FR2907011B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0609077A 2006-10-17 2006-10-17 USE OF CITRULLINE FOR THE TREATMENT OF DENUTRITION CONDITIONS Expired - Fee Related FR2907011B1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0609077A FR2907011B1 (en) 2006-10-17 2006-10-17 USE OF CITRULLINE FOR THE TREATMENT OF DENUTRITION CONDITIONS
PCT/FR2007/001407 WO2008049984A2 (en) 2006-10-17 2007-08-29 Use of citrulline for treating undernutrition conditions
CA002666538A CA2666538A1 (en) 2006-10-17 2007-08-29 Use of citrulline for treating undernutrition conditions
CNA2007800424825A CN101605538A (en) 2006-10-17 2007-08-29 Citrulline is used for the treatment of the purposes of undernutrition conditions
US12/445,820 US20100298437A1 (en) 2006-10-17 2007-08-29 Use of citrulline for treating undernutrition conditions
JP2009532837A JP2010506887A (en) 2006-10-17 2007-08-29 Use of citrulline for the treatment of undernourishment
EP07823453.1A EP2081564B1 (en) 2006-10-17 2007-08-29 Use of citrulline for treating undernutrition conditions
IL198182A IL198182A0 (en) 2006-10-17 2009-04-16 Use of citrulline for treating undernutrition conditions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0609077A FR2907011B1 (en) 2006-10-17 2006-10-17 USE OF CITRULLINE FOR THE TREATMENT OF DENUTRITION CONDITIONS

Publications (2)

Publication Number Publication Date
FR2907011A1 FR2907011A1 (en) 2008-04-18
FR2907011B1 true FR2907011B1 (en) 2010-05-14

Family

ID=37888135

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0609077A Expired - Fee Related FR2907011B1 (en) 2006-10-17 2006-10-17 USE OF CITRULLINE FOR THE TREATMENT OF DENUTRITION CONDITIONS

Country Status (8)

Country Link
US (1) US20100298437A1 (en)
EP (1) EP2081564B1 (en)
JP (1) JP2010506887A (en)
CN (1) CN101605538A (en)
CA (1) CA2666538A1 (en)
FR (1) FR2907011B1 (en)
IL (1) IL198182A0 (en)
WO (1) WO2008049984A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2913885B1 (en) * 2007-03-22 2012-07-20 Univ Paris Descartes USE OF CITRULLINE FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH INCREASED CARBONYLATION OF PROTEINS
DE102007016715A1 (en) * 2007-04-04 2008-10-09 Evonik Degussa Gmbh Nutritional supplement containing alpha-keto acids
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
FR2970414B1 (en) 2011-01-14 2013-03-22 Univ Paris Descartes PREVENTIVE ACTION OF CITRULLINE ON THE SPONTANEOUS DEVELOPMENT OF TUMORS
ES2636479T3 (en) 2013-06-10 2017-10-05 N.V. Nutricia Muscle preservation in the overweight or obese adult during a weight loss program
FR3009963B1 (en) 2013-09-03 2017-03-03 Biolis COMPOSITION FOR CONTROLLING LOCOMOTION DISORDERS
PL2875736T3 (en) 2013-11-26 2017-02-28 Citrage N-Carbamoylputrescine to enhance muscle protein synthesis
JPWO2015137387A1 (en) * 2014-03-11 2017-04-06 協和発酵バイオ株式会社 Muscle enhancer
CN104263550A (en) * 2014-09-11 2015-01-07 滁州斯迈特复合材料有限公司 Makeup solution glass bottle detergent
WO2017038991A1 (en) * 2015-09-04 2017-03-09 国立大学法人 筑波大学 Composition for muscle building and method for building muscle
KR102396603B1 (en) 2015-09-16 2022-05-11 원광대학교산학협력단 Composition for improving liver function comprising citrulline as an active ingredient
WO2017075289A1 (en) 2015-10-27 2017-05-04 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
EP3773013A1 (en) 2018-03-27 2021-02-17 N.V. Nutricia Insulin control in overweight or obese adult during life time intervention

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6306M (en) * 1966-12-15 1968-09-16
FR6305M (en) * 1966-12-15 1968-09-16
FR6304M (en) * 1966-12-15 1968-09-16
US4988724A (en) * 1988-12-09 1991-01-29 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
US5189025A (en) * 1988-12-09 1993-02-23 Board Of Regenets, The University Of Texas System Methods for the treatment of malignant disease in patients using citrulline containing amino acid solutions
FR2691359B1 (en) * 1992-05-20 1995-06-23 Krempf Michel NEW THERAPEUTIC APPLICATION OF 1-CITRULLINE MALATE.
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
FR2857262B1 (en) * 2003-07-08 2007-10-05 Biocodex Lab USE OF CITRULLINE IN THE CONTEXT OF INTESTINAL FAILURE

Also Published As

Publication number Publication date
JP2010506887A (en) 2010-03-04
EP2081564B1 (en) 2014-01-01
US20100298437A1 (en) 2010-11-25
WO2008049984A2 (en) 2008-05-02
EP2081564A2 (en) 2009-07-29
CA2666538A1 (en) 2008-05-02
WO2008049984A3 (en) 2008-06-19
CN101605538A (en) 2009-12-16
IL198182A0 (en) 2009-12-24
FR2907011A1 (en) 2008-04-18

Similar Documents

Publication Publication Date Title
FR2907011B1 (en) USE OF CITRULLINE FOR THE TREATMENT OF DENUTRITION CONDITIONS
FR20C1066I2 (en) GDF TRAPS FOR USE IN THE TREATMENT OF ANEMIA
FR2948016B1 (en) ORTHESIS FOR THE TREATMENT OF RHIZARTHROSIS
FR14C0050I1 (en) COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF MULTIPLE SCLEROSIS
FR2902324B1 (en) USE OF ELLAGIC ACID FOR THE TREATMENT OF CANITIA
FR2912833B1 (en) PANEL FOR ACOUSTIC TREATMENT
FR2882654B1 (en) USE OF DIOSMETIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF THROMBOTIC DISEASES
FR2932478B1 (en) COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS.
FR2912761B1 (en) PROTHETIC KNIT FOR THE TREATMENT OF PROLAPSUS
ATE434620T1 (en) DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP2139475A4 (en) The use of pde7 inhibitors for the treatment of movement disorders
FR2915102B1 (en) USE OF ANTI-CXCR4 ANTIBODY FOR THE TREATMENT OF CANCER
FR2948687B1 (en) USE OF MICROARN FOR THE TREATMENT OF CHRONIC RESPIRATORY DISEASES
FR2897533B1 (en) OXIDIZING AGENT FOR THE TREATMENT OF HAIR
FR2896422B1 (en) DRAINAGE SYSTEM FOR THE TREATMENT OF HYDROCEPHALY
FR2906468B1 (en) USE OF COMPOUNDS OF THE AVERMECTIN FAMILY FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
FR2899128B1 (en) USE OF DELEUCOCYTATION FILTERS FOR THE PURIFICATION OF DEFENSINS
FR2902320B1 (en) USE OF BUTYLATED HYDROXYANISOLE FOR THE TREATMENT OF CANITIA
FR2954124B1 (en) USE OF 2,3-DIHYDROXYPROPYL DODECANOATE FOR THE TREATMENT OF SEBORRHEA
FR2917947B1 (en) PHYTOSANITARY COMPOSITION FOR THE PREVENTIVE AND CURATIVE TREATMENT OF MILDIOU
FR2889518B1 (en) SYSTEM FOR THE TREATMENT OF DOMESTIC WASTEWATER
FR2905868B1 (en) COMPOSITION FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
FR2910813B1 (en) NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
FR2928153B1 (en) NEW ADDITIVE FOR THE TREATMENT OF RESULTS STEELS
FR2868312B1 (en) PATCH FOR THE TREATMENT OF LIP

Legal Events

Date Code Title Description
CD Change of name or company name
CL Concession to grant licences
TQ Partial transmission of property

Owner name: BIOCODEX, FR

Effective date: 20150824

Owner name: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, FR

Effective date: 20150824

Owner name: UNIVERSITE PARIS DESCARTES, FR

Effective date: 20150824

Owner name: I.N.R.A.INSTITUT NATIONAL DE LA RECHERCHE AGRO, FR

Effective date: 20150824

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

CD Change of name or company name

Owner name: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, FR

Effective date: 20201103

Owner name: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULT, FR

Effective date: 20201103

Owner name: UNIVERSITE PARIS DESCARTES, FR

Effective date: 20201103

Owner name: BIOCODEX, FR

Effective date: 20201103

ST Notification of lapse

Effective date: 20220605

CD Change of name or company name

Owner name: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, FR

Effective date: 20221006

Owner name: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULT, FR

Effective date: 20221006

Owner name: BIOCODEX, FR

Effective date: 20221006

Owner name: UNIVERSITE PARIS CITE, FR

Effective date: 20221006